July 2025 Content Release Copied

07/31/20252025 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile Documentation

Additions

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.

Curbside Connect with Dr. Yardley for HR+, HER2-, and Triple Negative patients is now available for Breast Cancer.

Lab Analytes & Panels

Precision Medicine Updates

The Guardant360 TissueNext PD-L1 panel has been retired. Additionally, the Guardant360 TissueNext panel has been renamed to the Guardant360 Tissue panel.

The FoundationOne Heme panel and the Guardant Reveal Panel are now available in PMO through the PMO drawer.

Additions and Updates

  • ANTI GM-1, IgG panel
  • ATM gene panel
  • BARD1 gene panel
  • BRIP1 gene panel
  • difficile detection
  • CDKN2A gene panel
  • Clobazam, serum, ng/mL
  • Compass with clonoSEQ – blood panel
  • Compass with clonoSEQ – bone marrow panel
  • Compass without clonoSEQ – blood panel
  • Compass without clonoSEQ – bone marrow panel
  • Comprehensive hemeSeq panel
  • CSF AGNA-1
  • CSF amphiphysin antibody
  • CSF ANNA type 3
  • CSF Anti-Hu Ab
  • CSF Anti-Ri Ab
  • CSF CASPR2 antibody, IFA
  • CSF CRMP-5 IgG
  • CSF LGI1 antibody, IFA
  • CSF paraneoplastic Ab interpretation
  • CSF paraneoplastic Ab profile
  • CSF PCA type-1 (Anti-Yo) Ab
  • CSF purkinje cell cyto Ab type 2
  • CSF purkinje cell cyto Ab type Tr
  • Decipher (Veracyte)
  • Desmethylclobazam, serum, ng/mL
  • Est average glucose (eAG), mg/dL
  • F12 gene panel
  • F2 gene panel
  • F5;F2 gene panel
  • FoundationOne Ventana MET (SP44) panel
  • GM-1 IgG autoantibodies interpretation
  • GM-1 IgG autoantibodies, %
  • Guardant360 Tissue PD-L1 panel
  • Hgb A1C, %
  • Hgb electrophoresis pathologist
  • Invitae chromosomal microarray analysis (CMA) panel
  • Invitae epilepsy panel
  • Invitae hyper IgE syndrome panel
  • Invitae iron related disorders including anemia panel + Invitae comprehensive porphyrias panel
  • KRT5 gene panel
  • Lanreotide panel
  • MUTYH gene panel
  • MXD#, x10^3/uL
  • Parvovirus B19 DNA quantitative by PCR panel
  • PDE10A Ab IFA, S
  • SDHB gene panel
  • STK11 gene panel
  • Trypanosoma cruzi Ab, confirmation
  • Varicella zoster, IgG, S/CO

Medications

Additions

  • Acasunlimab invest (GEN1046 invest IV)
  • Anitocabtagene Autoleucel invest (KITE-772 invest IV)
  • AVZO-1418 invest IV
  • BL-M11D1 invest IV
  • BMS-986507 invest IV
  • Compound Benzocaine-Lidocaine-Tetracaine Topical 20 %-10 %-10 %
  • Compound Budesonide Nasal Irrigation
  • DR-0202 invest IV
  • ENV-501 invest IV
  • Fiber Supplement (inulin) Oral
  • GEN1046 invest IV
  • Givinostat invest Oral
  • IBI3009 invest IV
  • Igrelimogene Litadenorepvec invest (TILT-123 invest IV)
  • Izalontamab Brengitecan invest (BMS-986507 invest IV)
  • JZP815 invest Oral
  • KITE-772 invest IV
  • KQB168 invest Oral
  • Prevagen Oral
  • TILT-123 invest IV
  • TOS-358 invest Oral
  • TPN Electrolytes IV

Updates

Medications Updates
BG-68501 invest Oral New Form available:

  • 100 mg tablet
Gallium 68Ga Gozetotide or 68Ga Ga-PSMA-11 invest IV Remove Instructions:

  • Administered doses should not be lower than 111 MBq or higher than 180 MBq

New Instructions available:

  • Administered doses should not be lower than 111 MBq or higher than 259 MBq
  • Administered doses should not be lower than 3 mCi or higher than 7 mCi
HER3-DXd invest IV New Alias available:

  • Patritumab Deruxtecan (MK-1022) invest
NVL-655 invest Oral New Alias available:

  •  Neladalkib invest
Rituximab IV Remove Maximum Single Dose:

  • 1,250 mg

New Maximum Single Dose available:

  • 1,875 mg
Rituximab-abbs IV Remove Maximum Single Dose:

  • 1,250 mg

New Maximum Single Dose available:

  • 1,875 mg
Rituximab-arrx IV New Maximum Single Dose available:

  • 1,875 mg
Rituximab-pvvr IV Remove Maximum Single Dose:

  • 1,250 mg

New Maximum Single Dose available:

  • 1,875 mg
Taletrectinib invest Oral New Name available:

  • AB-106/DS-6051b invest Oral

New Form available:

  • 100 mg capsule

New Alias available:

  • Taletrectinib invest
Zelenectide pevedotin invest (BT8009 invest IV) New Quick SIG Pick available:

  • 3 mg/m2 intravenously As Directed
  •  4.2 mg/m2 intravenously As Directed
  • 6 mg/m2 intravenously As Directed

Regimen Library

Additions

Regimen Name Diagnosis
Daratumumab IV + Bortezomib D1,8,15 + Dexamethasone Q21D
(Part 1 of 2)		 Multiple Myeloma (MM)
Daratumumab IV + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Part 1 of 2) Multiple Myeloma (MM)
Daratumumab IV + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Part 1 of 2: C1 Split Dosing) Multiple Myeloma (MM)
Daratumumab SQ + Bortezomib D1,8,15 + Dexamethasone Q21D
(Part 1 of 2)		 Multiple Myeloma (MM)
Daratumumab SQ + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Part 1 of 2) Multiple Myeloma (MM)
Daratumumab SQ + Lenalidomide + Bortezomib D1,8,15,22 + Dexamethasone (RVD) (PERSEUS) Q28D (Part 1 of 2) Multiple Myeloma (MM)
Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) C1 D1,22,43,64 (Q21D) fb Nivolumab SQ C2+ D1,29,57 (Q28D) Maintenance Q84D Hepatocellular Carcinoma (HCC); Melanoma, Skin; Melanoma, Uvea, Ciliary Body/Choroid
Pomalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone Q28D Multiple Myeloma (MM)
Taletrectinib Q30D Lung Cancer, Non-small Cell (NSCLC)
Tislelizumab-jsgr Q14D Anal Cancer (Parent), Colon Cancer, Esophageal Cancer (Parent), Hepatocellular Carcinoma (HCC), Rectal Cancer
Tislelizumab-jsgr Q28D Anal Cancer (Parent), Colon Cancer, Esophageal Cancer (Parent), Hepatocellular Carcinoma (HCC), Rectal Cancer

Updates

The Collaborative Care Committee recently voted to pre-check magnesium IV pre-hydration in all cisplatin-containing regimens. This update will begin in July and be completed with the August content release.

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • All Problems
  • Anal Cancer (Parent)
  • Bile Duct Cancer (Parent)
  • Bladder Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colon Cancer
  • Esophageal Cancer (Parent)
  • Fallopian Tube Cancer
  • Gallbladder Cancer
  • Gastric Cancer
  • Head and Neck Cancer (Parent)
  • Hepatocellular Carcinoma (HCC)​
  • Leukemia, Chronic Lymphocytic (CLL)
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lung Cancer, Small Cell (SCLC)
  • Lymphoma, Hodgkin (HL)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Melanoma, Skin
  • Melanoma, Uvea, Ciliary Body/Choroid​
  • Multiple Myeloma (MM)
  • Ovarian and Primary Peritoneal Cancer
  • Pancreatic Cancer
  • Rectal Cancer
  • Renal Pelvis and Ureter Cancer
  • Testicular Cancer (Parent)
  • Urethral Cancer
  • Uterine Cancer (Parent)
  • Vulva Cancer

Renames

Previous Name New Name
Denosumab (Prolia) Q6M Denosumab (60 mg) Q6M
Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) Q21D Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) C1 D1,22,43,64 (Q21D) fb Nivolumab IV C2+ D1,29,57 (Q28D) Maintenance Q84D

Removals

Regimen Name Diagnosis
Influenza Vaccines 2024-2025 All Problems

Billing & HCPCS Codes

Updates

Medication HCPCS Codes
Albumin, iodinated I-131 IV A9524 per:

  • 5 mci
  • 5 microCi
Atidarsagene autotemcel IV J3391 per 6.6 x 10e6 CD34+ cells
Denosumab-bmwo Subcutaneous
(120 mg/1.7 mL – Osenvelt)		 J3590 per 120 mg
Denosumab-bmwo Subcutaneous (60 mg/mL – Stoboclo) J3590 per 60 mg
Denosumab-bnht Subcutaneous
(120 mg/1.7 mL – Bomyntra)		 J3590 per 120 mg
Denosumab-bnht Subcutaneous
(60 mg/mL – Conexxence)		 J3590 per 60 mg
Foscarbidopa-foslevodopa Continuous Subcutaneous Infusion J7356 per:

  • 0.25 mg
  • 0.02083 mL
Foscarbidopa-foslevodopa Subcutaneous J7356 per:

  • 0.25 mg
  • 0.02083 mL
Garadacimab-gxii Subcutaneous Auto-Injector J3590 per 200 mg
Linvoseltamab-gcpt IV J9999 per 200 mg
Meloxicam IV J3490 per 30 mg
Nipocalimab-aahu IV J3590 per 1200 mg
Nivolumab-hyaluronidase-nvhy Subcutaneous 600 mg-10,000 unit/5 mL J9289 per:

  • 2 mg
  • 0.016667 mL
Ustekinumab-srlf IV Q5098 per 1 mg
Ustekinumab-srlf Subcutaneous Q5098 per 1 mg

NDC – HCPCS Crosswalk

Additions

  • 51407092911
  • 51407093011
  • 69448001763
  • 69448001863
Medication (Brand) HCPCS Codes NDC
Ustekinumab-srlf IV (Imdulsa) Q5098 per 1 mg
  • 51407093111
  • 69448001926
Ustekinumab-srlf Subcutaneous (Imdulsa) Q5098 per 1 mg